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Purpose: The purpose of the current study was to examine the ocular pathogenesis and immune reaction in mice after
intravitreal dispase injection.
Methods: Three microliters of dispase at a concentration of 0.2 U/μl were injected into the vitreal cavities of 4–6-week-
old mice. Hematoxylin and eosin staining, immunofluorescence analysis, and electroretinograms of the eyes were then
performed to assess ocular changes, and enzyme-linked immunospot assays and intracellular staining of single-cell
suspensions of the spleens were used to detect immune changes during an 8 week observation period.
Results: Neutrophils were the main inflammatory infiltrating cells appearing at the anterior chamber. No cluster of
differentiation (CD)3+ labeled T cells, F4/80+ labeled macrophages, or CD56+ labeled natural killer cells were found in
the vitreal cavities or retinas in dispase-injected mice within 5 days after injection. Proliferative vitreoretinopathy (PVR)-
like signs first appeared at 2 weeks, gradually increased thereafter, and reached peak values at 8 weeks. There was a
statistically  significant  difference  in  b-wave  amplitudes  between  the  PVR  and  saline-control  eyes.  Enzyme-linked
immunospot assays and intracellular staining showed that specific CD4+ and CD8+ labeled T cells were not involved in
dispase-injected mice.
Conclusions: Our data show that neutrophils in the anterior chamber and PVR-like signs in the retinas were found, and
that specific immune reactions were not involved after intravitreal dispase injection in mice.
Dispase, a proteolytic enzyme able to harvest and culture
cells due to its ability to cleave the basal membrane in various
tissues, can be used as an intravitreal injection material to
induce proliferative vitreoretinopathy (PVR) in the eyes of
mice [1,2] and rabbits [3-9]. PVR is the most common cause
of recurrent retinal detachment after retinal detachment repair,
occurring in 5%–11% of patients [10,11]. Basic research has
indicated that PVR is characterized by the formation of scar-
like fibrous tissue containing myofibroblasts derived from
transdifferentiated retinal pigment epithelial (RPE) cells and
other cell types, such as glial cells, that have entered the
vitreous  cavity  and  induced  the  contraction  of  cellular
membranes within the vitreous cavity on both detached retinal
surfaces [12-14].
Dispase is a heterogeneous protein, and its intravitreal
injection may cause some immune reaction and ocular change,
not only in the vitreous and retina, but also in the anterior
chamber. The autoimmune hypothesis has been prompted by
the observation that a PVR-like disease can be induced in
rabbits by immunization with the retinal autoantigens opsin,
antigen  S,  and  interphotoreceptor  retinoid-binding  protein
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[15]. Also apparently supporting the autoimmune hypothesis
is the fact that PVR patients display signs of active immune
processes in their epiretinal or subretinal membranes, vitreous
cavities, subretinal fluids, and serum samples [16-22]. Similar
signs of immune activation have been reported for the cells
present in the vitreous cavities and subretinal fluids of PVR
patients [19,23-26]. Sera of PVR patients have been reported
to contain increased concentrations of S-antigen (S-Ag) [27]
and S-Ag-specific autoantibodies [28]. The induction of these
autoantibodies in particular implies that after iatrogenic eye
injury, the exposure to S-Ag triggers an autoantigen-specific
B cell response. Since autoantibody production of protein self-
antigens  is  strictly  dependent  on  cluster  of  differentiation
(CD)4 T cell help [29], the presence of these antibodies also
implies an autoimmune T cell response against these self-
proteins.  Thus,  these  autoreactive  T  and  B  cells  could
conceivably mediate the pathology underlying PVR. While
the  above  findings  are  consistent  with  an  autoimmune
hypothesis for PVR, they do not prove it, and it has been
difficult  to  establish  whether  the  immune  reactions  seen
represent  the  cause  or  merely  an  epiphenomenon  of  the
disease [30].
Can dispase trigger autoreactive B or T cell response? To
the best of our knowledge, the pathogenesis of the anterior
chamber  and  immune  reactions  has  not  been  well
documented. Therefore, it is important to study the ocular
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887pathogenesis and immune reaction after intravitreal dispase
injection in mice. In the present study, we analyzed these
outcomes after intravitreal dispase injection during an 8 week
observation period.
METHODS
Mice: Four- to six-week-old wild-type C57BL/6 mice were
purchased from the South Medical University Animal Center
(Guangzhou,  China).  Animal  husbandry  and  experimental
procedures  were  approved  by  the  Animal  Research
Committee of the Zhongshan Ophthalmic Center, Sun Yat-
sen University (Guangzhou, China). All animals were housed
in  a  specific  pathogen-free  biohazard  level-2  facility
maintained  by  the  Zhongshan  Ophthalmic  Center  in
accordance  with  the  Association  for  Assessment  and
Accreditation of Laboratory Animal Care guidelines.
In vivo model of proliferative vitreoretinopathy induced by
dispase intravitreal injection: The murine PVR model was
induced  by  dispase  (Gibco,  Tokyo,  Japan),  as  previously
described [1,2]. Intravitreal injections were performed in the
dorsonasal  quadrant  (1  o’clock)  1.5  mm  away  from  the
corneal  limbus  of  the  right  eye.  Three  μl  of  dispase  at  a
concentration of 0.2 U/μl were injected into the vitreal cavities
using a Hamilton syringe fitted with a 30 G needle. Control
animals received 3 μl of sterile saline solution. Female mice,
4–6 weeks old, were anesthetized with 4.3% chloral hydrate
(0.01  ml/g;  Zhongshan  Ophthalmic  Center,  Sun  Yat-sen
University,  Guangzhou,  China).  Pupils  were  dilated  with
0.5% tropicamide (Shenyang Sinqi Pharmaceutical Co., Ltd).
Intravitreal  injections  were  performed  in  the  dorsonasal
quadrant (1 o’clock) 1.5 mm away from the corneal limbus of
the right eye. Three μl of dispase at a concentration of 0.02 U/
μl were injected into the vitreal cavities using a Hamilton
syringe fitted with a 30 G needle. Control animals received
3 μl of sterile saline solution. All experimental procedures
adhered to the guidelines of the Association for Research in
Vision and Ophthalmology Statement for the Use of Animals
in Ophthalmic and Vision Research.
Experimental groups: The mice were divided into a dispase-
injected  group  and  a  saline-injected  control  group  (n=92,
n=68). These two groups were then equally divided into seven
subgroups (n=6, n=4) at the 0 h, 4 h, 8 h, 12 h, 24 h, 48 h, and
5 day time points and five subgroups (n=10, n=8) at the 1, 2,
4, 6, and 8 week time points.
Follow-up examinations and the development of proliferative
vitreoretinopathy:  The  injected  eyes  were  examined  and
assessed—including  the  cornea,  lens  opacity,  intravitreal
hemorrhages, and the fundus—using a surgical microscope at
each  time  point  after  intravitreal  injection.  Because
intravitreal hemorrhages and cataracts have often occurred in
various studies [31], clinical PVR-like signs were defined as
the presence of one of the following three symptoms: retinal
folds, epiretinal membranes, and an uneven iris at 1, 2, 4, 6,
and 8 weeks during this experiment. This evaluation system
was modified from Cantó Soler MV [1,2].
Tissue preparation and histological and immunofluorescence
analysis: Mice used for histological studies were sacrificed at
0 h, 4 h, 8 h, 12 h, 24 h, 48 h, and 5 days or 1, 2, 4, 6, or 8
weeks after injection, and dissected eyes were cryopreserved
using the optimal cutting temperature (Sakura Finetechnical,
Torrance, CA) compound. For immunofluorescence analysis
and  hematoxylin  and  eosin  (H&E)  staining,  consecutive
6  μm  thick  sections  of  each  sample  were  cut  and  thaw-
mounted onto poly-L-lysine-coated glass slides. For confocal
microscopy,  double  immunostaining  was  performed  using
two primary antibodies incubated respectively for about 20 h
at  room  temperature  and  then  incubated  with  secondary
antibodies for about 1 h in the dark. Primary antibodies served
as markers, including glial acidic fibrillary protein (GFAP),
glutamine  synthase  (GS),  retinal  pigment  epithelium  65
(RPE65), alpha smooth muscle actin (a-SMA), F4/80, anti-
CD3, and anti-CD56. Dilutions and the source of each primary
antibody are described in Table 1. Negative controls were
made by omitting the primary antibodies. Three secondary
antibodies  were  used  in  this  study:  R-phycoerythrin-
conjugated goat antirat IgG (1:10; Southern Biotechnology
Associates,  Inc.,  Birmingham,  AL),  R-phycoerythrin-
conjugated  goat  antimouse  IgG  (1:10;  Southern
Biotechnology  Associates,  Inc.),  and  fluorescein
isothiocyanate–labeled  goat  antirabbit  IgG  (1:10;  KPL,
Gaithersburg, MD). Sections were washed four times in PBS
(5 min each time) and mounted under coverslips in antifade
solution (Applygen Technologies Inc., Beijing, China) for
observation with a fluorescence microscope (Carl Zeiss Far
East Co. Ltd., HK).
TABLE 1. CHARACTERISTICS OF PRIMARY ANTIBODIES USED IN THIS STUDY.
Antigen Antibody class Source Dilution
RPE65 Mouse monoclonal Abcam plc 332 Cambridge Science Park, Cambridge, UK 1:100
GFAP Mouse monoclonal Abcam plc 332 Cambridge Science Park, Cambridge, UK 1:500
GS Rabbit polyclonal Abcam plc 332 Cambridge Science Park, Cambridge, UK 1:50
a-SMA Rabbit polyclonal Abcam plc 332 Cambridge Science Park, Cambridge, UK 1:100
CD3 Rat monoclonal R&D Systems, Inc, USA 1:50
CD56 Rabbit polyclonal Boster Biologic Technology, WuHan, China 1:100
F4/80 Rat monoclonal Abcam plc 332 Cambridge Science Park, Cambridge, UK 1:10
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888Electroretinograms: Electroretinograms (ERGs) of dispase-
injected PVR mice (n=14) and saline-injected control mice
(n=14) were performed at 6 and 8 weeks in a full-field dome,
using methods similar to those used in the clinic and stimuli
comparable to those specified by the International Society for
Clinical Electrophysiology of Vision [32]. The eyes were
dilated with 0.5% tropicamide and dark-adapted for at least
30  min.  Mice  were  anesthetized  with  a  saline  solution
containing  ketamine  hydrochloride  (30  mg/kg)  and
chlorpromazine hydrochloride (15 mg/kg). A gold-wire coil
placed on one cornea was referenced to a needle electrode in
the scalp. A needle electrode in the tail served as ground. The
recordings were made using the Roland Ganzfeld system and
PC-based signal acquisition and analysis software (Fa. Roland
Consult,  Brandeburg,  Germany).  Scotopic,  mesopic,
photopic, and oscillatory potentials, as well as 30 Hz flicker
ERG responses were recorded. The bright-flash response was
elicited using the ISCEV standard flash of 2.4 cd/m2 (settings:
−25dB  flash,  fix  on,  backlight  off  0.5HZ).  After  light
adaptation of 10 min with a steady background illumination
of 10 cd/m2, photopic responses (settings: 0dB standard flash,
fix on, backlight off 0.2HZ) and 30 Hz flicker ERGs were
recorded. In this way, the a- and b-wave amplitudes and the
implicit  times  of  the  standard  responses  were  determined
[33].
Enzyme-linked immunospot assay: Mice were sacrificed at 1,
2,  4,  6,  or  8  weeks  after  injection.  An  enzyme-linked
immunospot (Enzyme-Linked ImmunoSpot assay [ELISpot],
Cellular  Technology  Ltd,  Cleveland,  OH)  assay  was
performed, as described by Jager et al. [34]. In brief, single-
cell suspensions were prepared from the spleens of individual
mice.  The  immunospot  plates  (MAHAS45;  Millipore,
Bedford, MA) had the regular format of 96 wells. Ethanol
(70%) was added at 15 μl per well for prewetting, and the
plates were washed three times with PBS. After washing, the
plates were coated with antimouse-interferon (IFN)-γ capture
Ab (BD, San Diego, CA) at 5 μg/ml in PBS and antimouse-
interleukin  (IL)-2  capture  Ab  (BD)  at  5  μg/ml  in  PBS,
respectively; they were then stored overnight at 4 °C. The
plates  were  then  blocked  with  Roswell  Park  Memorial
Institute (RPMI) 1640 medium for 2 h at room temperature
and washed three times with PBS. The single-cell suspensions
were plated in complete RPMI 1640 and added at 1×105 cells
per well to the 96-well plates. In each well, dispase (Gibco,
Tokyo, Japan) was added as a stimulus at 0.02 U/ml; as a
positive control, 2 μg/ml phytohemagglutinin (PHA; Fluka,
Sigma, Carlsbad, CA) was added in the absence of dispase.
Finally, as a negative control, PBS was added in the absence
of dispase. After 20 h incubation at 37 °C in CO2 incubators
and  washing,  2  μg/ml  of  biotinylated  antimouse-IFN-γ
detection Ab (BD) in PBS/BSA (BSA)/Tween (10 g/l BSA
with 0.5% Tween) and 2 μg/ml antimouse-IL-2 detection Ab
(BD) in PBS/BSA/Tween (10 g/l BSA with 0.5% Tween)
were added. After 2 h incubation at room temperature and
washing  three  times  with  PBS/Tween,  100  uL/well  of
streptavidin- horseradish peroxidase (HRP; 1:100 dilution;
BD)  in  PBS/BSA/Tween  was  added  for  1  h  at  room
temperature and then washed with PBS/Tween, followed by
PBS. The 3-amino-9-ethylcarba (AEC) working solution was
freshly prepared by mixing 9.8 ml AEC substrate solution
(BD) with 200 μl AEC chromogen solution (BD); 100 ul of
the mixture was plated per well. The plates were developed
for 15–20 min, after which the reaction was stopped by rinsing
with tap water. The plates were air dried overnight and read
by the Champ Spot II ELISpot reader (Sage Creation, Beijing,
China). The indicated spot numbers per well represent the
mean values of three replicates.
Intracellular  staining  and  flow  cytometry:  Intracellular
staining  and  a  flow  cytometry  assay  were  performed,  as
previously described [35]. Single-cell suspensions from the
spleens of model mice at 4 weeks were prepared. Dispase was
added as a stimulus at 0.02 U/ml; as a positive control, 2 μg/
ml PHA (Fluka; Sigma, Louis, MO) were added in the absence
of  dispase.  As  a  negative  control,  PBS  was  added  in  the
absence  of  dispase.  After  1  h  of  incubation,  Brefeldin  A
(Sigma) at a final concentration of 10 μg/ml was added to
cultures to enable intracellular protein to accumulate in all
stimulations. After incubation for a total of 5 h, the cells were
harvested,  washed  twice  with  PBS,  fixed  with  4%
paraformaldehyde, and permeabilized with PBS containing
0.1% saponin (Fluka) plus 0.5% BSA buffer overnight at 4 °C.
They were then stained with anti-CD4, anti-CD8, anti-IFN-
γ, or isotype control Abs (BD) for 30 min at 4 °C and washed
twice with PBS before being resuspended in PBS containing
0.5%  BSA  and  0.1%  NaN3.  Cells  were  acquired  using  a
FACSCalibur flow cytometer (BD Biosciences, San Diego,
CA),  and  FACS  data  were  analyzed  using  FlowJo  (BD
Biosciences). Isotype-matched controls for cytokines were
included in each staining.
Data and statistical analysis: Results are expressed as mean
±standard deviation (SD). ERG data were compared using the
Student t test. A value of p<0.05 was considered statistically
significant.
RESULTS
Early inflammatory infiltration (occurring at 0, 4, 8, 12, 24,
and 48 h, and 5 days): In the dispase-injected group, the
results of H&E-stained sections of the model eyes showed
early inflammatory infiltration after dispase injection at 0, 4,
8, 12, 24, and 48 h and 5 days. Neutrophils were the main
inflammatory  infiltrating  cells  appearing  at  the  anterior
chamber (Figure 1) instead of the vitreous cavity (Figure 2)
during  early  inflammatory  infiltration.  The  neutrophils
appeared from hour 8 to hour 48 at the anterior chamber, as
shown in Figure 1 and Figure 2. However, in the saline-
injected control groups, the H&E-stained sections exhibited
normal eye morphology, without inflammatory infiltration
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889Figure 1. Early inflammatory infiltration profile (0–5 day time points) in diapase-injected and saline-injected control mice. Panels A-G shows
inflammatory infiltration profile 0–5 days. Panel H shows a control. Neutrophils appeared from hour 8 (C) to hour 48 (F) in the anterior
chamber of dispase-injected eyes but not saline-injected eyes (hematoxylin and eosin [H&E] staining, scale bar 100 μm). All the arrows of
panels C-F shows neutrophils.
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890cells, at all time points. No CD3+ labeled T cells, F4/80+
labeled macrophages, or CD56+ labeled natural killer (NK)
cells were observed in the vitreous cavities or retinas at any
early time point in either of the two groups (Figure 3).
Proliferative vitreoretinopathy development at 1, 2, 4, 6, and
8 weeks: After dispase injection, hemorrhages, cataracts, and
PVR were observed in the dispase-injected groups (Figure 4).
PVR-like signs first appeared at 2 weeks; subsequently, they
gradually increased and reached their peak values at 8 weeks.
The PVR percentages at 1, 2, 4, 6, and 8 weeks were 0%, 23%,
44%, 70%, and 75%, respectively, in the dispase-injected
groups. H&E-stained frozen sections clearly showed marked
proliferative  membranes,  retinal  detachment,  serous  fluid
between  the  RPE  and  the  sensory  retinas,  and  destructed
retinas and lenses. In the process of PVR development, the
RPE65, GFAP, GS, and a-SMA labeled cells were involved
Figure 2. Ocular morphology during early inflammatory infiltration phase showed retinal structure damaged, in diapase-injected eyes but
relatively intact in saline-injected eyes (H&E staining, scale bar 100 μm; A-K).
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891in  the  PVR  eyes  of  mice  (Figure  5).  No  structural
abnormalities were found in the control eyes at the same time
points.
Electroretinogram results: As shown in Figure 6 and Table 2,
mesopic  ERG  (0dB  standard  flash,  fix  on,  backlight  off
0.2HZ) data showed decreases in the amplitude of the a-wave
in  dispase-injected  PVR  eyes,  suggesting  photoreceptor
dysfunction,  as  well  as  reductions  in  b-wave  amplitudes,
indicating  that  retinal  interneurons  (bipolar  cell  function)
were affected as well. However, scotopic ERGs (−25dB flash,
fix on, backlight off 0.5HZ) also showed significant decreases
in the b-wave amplitudes of dispase-injected PVR eyes, but
no decreases in the a-wave amplitudes of dispase-injected
PVR  eyes,  indicating  that  rod  cell  function  was  partially
preserved.
Enzyme-linked immunospot assay: At the 1, 2, 4, 6, and 8 week
time points, IFN-γ values were only detected in the single-cell
suspensions of the T cells of dispase-injected mice at 4 and 8
weeks. However, when compared with those in the positive
control (stimulated with PHA), there was no immune reaction
in dispase-injected mice or in saline-injected mice (Figure 7).
IL-2 was not detected at 1, 2, 4, 6, or 8 weeks in either dispase-
injected mice or saline-injected mice.
Intracellular staining: To test if IFN-γ was secreted from the
spleens of the dispase-injected mice at 4 weeks, intracellular
staining was performed. As shown in Figure 8, there were
IFN-γ+/CD4+ (0.061%) or IFN-γ+/CD8+ (0.23%) T cells in
the  single-cell  suspensions  from  the  spleens  of  dispase-
injected mice at 4 weeks. The above results indicate that IFN-
γ was not secreted by CD4+ or CD8+ labeled T cells in
dispase-injected mice.
DISCUSSION
Recently, there has been an increasing trend to induce the PVR
model  using  dispase  [1-9].  In  our  study,  we  successfully
replicated the murine PVR model and observed the ocular
pathogenesis and immune reaction after intravitreal injection
of dispase. This was the first demonstration indicating that
neutrophil cells appeared in the anterior chamber of eyes and
that  specific  immune  reactions  were  not  involved  after
intravitreal dispase injection in mice.
PVR can be induced via intravitreal injection of different
revulsants, such as RPE cells [36,37], macrophages [38,39],
and fibroblasts [40]. Compared with these revulsants, dispase
is  easily  available  and  does  not  lead  to  exogenous  cell
development in the PVR model. Hence, in the mouse PVR
model, dispase induced a PVR-like condition with a strong
contribution  of  macrophage-  and  glial-derived  cells  [1].
Regarding  the  rabbit  PVR  model,  several  authors  have
reported effects of matrix metalloproteinases [4] and a DNA-
RNA chimeric ribozyme-targeted proliferating cell nuclear
antigen [5]. Researchers have also reported Müller glial cells
displaying upregulation of purinergic P2 receptor–mediated
responses [6,7] and the interaction of cell surface molecules,
extracellular matrix proteins, cytoskeletal elements [8], and a
foldable capsular vitreous body [9] in PVR. However, due to
complications  such  as  cataracts  and  lens  dissolution  after
dispase injection, the eye fundi of mice have been impossible
to  observe  via  microscope  in  this  and  other  studies  [31].
Therefore, we modified the PVR development from the five
scores  used  by  Suburo’s  group  [1]  to  three  scores.  Once
cataracts  and  uneven  irises  occur,  tractional  retinal
detachment is inevitable in model eyes. We confirmed this
result based on the H&E and immunofluorescence analysis of
the frozen sections.
Figure 3. Immunofluorescence analysis showed no cluster of differentiation (CD)3+ labeled T cells, F4/80+ labeled macrophages, or CD56+
labeled natural killer (NK) cells involved in dispase-injected eyes at 48 h time point (A, B). Bluish cells stained with Hoechst 33342 (scale
bar 100 μm).
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892Figure 4. Dispase-injected mice developed cardinal features of proliferative vitreoretinopathy (PVR). A: Ocular fundi of dispase-injected eye
and saline-injected control eye. Arrow shows PVR membranes. B: Hematoxylin and eosin (H&E) staining of dispase-injected PVR eye and
saline-injected control eye. Arrow shows proliferative epiretinal membranes (EM). C: PVR percentages at 1, 2, 4, 6, and 8-week time points
after dispase injection.
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893Figure 5. Immunofluorescence analysis showed alpha smooth muscle actin (α-SMA; A), glial acidic fibrillary protein (GFAP; B), glutamine
synthase (GS; E), and retinal pigment epithelia Protein 65 (RPE-65; F) in epiretinal membranes (EMs) of proliferative vitreoretinopathy (PVR)
model eyes, indicating fibroblast cells, Müller cells, astroglial cells, and RPE cells involved in the process of PVR. Hoechst 33342 for nucleic
acid stained alone (C, G). D is the merged picture of A-C, H the merged picture of E-G (a triple staining). Arrow shows EM.
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894Regarding the early stage of PVR, we first reported that
neutrophils  were  the  main  inflammatory  infiltrating  cells
appearing  at  the  anterior  chamber  instead  of  the  vitreous
cavity during early inflammatory infiltration (i.e., before 5
days), as shown in Figure 1, Figure 2 and Figure 3. One
explanation for these infiltrating cells during the time between
Figure 6. Electroretinograms (ERG) of the dispase-injected proliferative vitreoretinopathy (PVR) model eyes and saline-injected control eyes.
Scotopic ERGs showed significant decreases in b-wave amplitudes, but no decreases in a-wave amplitudes of dispase-injected PVR eyes
compared with saline-injected control eyes.
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8958 h and 48 h after dispase injection might be a break of the
blood vessel integrity near the ciliary body caused by dispase
itself or methodological variations. These neutrophils might
represent separate events in the etiology of PVR. In addition,
no CD3+ labeled T cells, F4/80+ labeled macrophages, or
CD56+ labeled NK cells appeared in the vitreous cavities or
retinas before 5 days. This is likely due to the strong digestive
functions of the dispase enzyme.
The  role  of  inflammatory  and  immune  cells  in  PVR
membranes in the late stage of PVR has been reported in
several studies [1,18,26,41]. Suburo’s group showed that CD3
immunoreactivity  was  not  detected  in  saline-  or  dispase-
injected eyes [1]. T lymphocytes were found in five of the
eight subretinal membranes. CD4+ T cells were demonstrated
in four of the membranes and CD8+ T cells in one of the
membranes. T cells bearing the IL-2 receptor were found in
two of four membranes studied. Macrophages were found in
four  membranes.  No  B  lymphocytes  or  neutrophils  were
observed,  and  there  were  no  significant  deposits  of
complement  or  immunoglobulins  [18].  The  findings  of
Canataroglu et al. suggest that IL-6 and IL-8 may be involved
in  the  pathogenesis  of  proliferative  diabetic  retinopathy
(PDR), PVR, and traumatic PVR. Cytological examination of
the  vitreous  specimens  revealed  a  predominance  of
macrophages (50%) in the PDR samples and a predominance
of  RPE  cells  (60%)  in  the  PVR  samples.  In  contrast,
neutrophils  predominated  (88%)  in  the  traumatic  PVR
samples [26]. Using the monoclonal antibodies EBM11 (pan
macrophage) and 27E10 (early inflammatory stage marker),
Esser    et    al.  [41]  observed that  macrophages     were
predominantly found in traumatic PVR. Inflammatory stage
macrophages  could  not  be  detected  in  PVR  following
rhegmatogenous retinal detachment and idiopathic macular
pucker. In a previous study, T lymphocytes were found in 18
of the 21 PVR specimens and generally constituted a small
percentage of the total cell number. CD4+ T cells were found
in 14 of the 18 membranes containing T cells. Three of six
frozen membranes contained T cells that were positive for the
IL-2 receptor. Cells positive for the macrophage/monocyte
marker were found in five of the 16 membranes studied. No
B lymphocytes or neutrophils were observed, and there were
no deposits of complement or immunoglobulins [42].
Our  observations  yielded  similar  results;  that  is,  the
intravitreal  dispase  injection  induced  PVR-like  signs.
Clinically significant PVR with retinal detachment developed
in 75% of mice at 8 weeks, which is very similar to the 75%
of mice [1] and 76% of rabbits [4] previously reported. In our
study, for confocal microscopy, double immunostaining for
RPE65, GFAP, GS, and a-SMA labeled cells was involved in
the development of PVR, which is very similar to other studies
[1,43]. GFAP is mainly expressed by astrocytes in the normal
retinas of several species. Müller cells’ staining for GFAP in
normal  retinas  is  very  faint.  However,  in  pathologically
changed  retinas,  Müller  cells  become  immunopositive  for
GFAP in retinal detachment and PVR. GS is a marker for
astrocytes.  In  retinas,  many  astrocytes  with  contact  to
ganglion  cells  also  express  GS.  A-SMA  is  expressed  by
myofibroblasts.  However,  transdifferentiated  RPE  cells  or
macroglial  cells  (astrocytes  as  well  as  Müller  cells)  in
epiretinal  membranes  of  PVR  eyes  can  also  express  this
molecule. The ERG results further confirmed that the retinal
functions of mice had been significantly damaged.
Our results regarding the ELISpot assay and intracellular
staining first showed that specific immune systems do not play
a major role in the pathogenesis of PVR. Although a great deal
of information supports the role of the immune system in the
development of PVR, the role of the immune system in the
pathogenesis  of  PVR  is  still  unclear.  Data  are  sometimes
contradictory,  and  it  is  difficult  to  establish  whether  the
immune alterations seen in PVR are causes or consequences
[30].  The  results  of  a  recent  study  did  not  support  the
assumption  that  CD44  has  a  functional  role  in  the
pathogenesis of PVR [8]. Although our ELISpot assay showed
that INF-γ was detected in the single-cell suspensions of the
T  cells  of  dispase-injected  mice  at  4  and  8  weeks,  when
compared with those in the positive control (stimulated with
TABLE 2. ERG DATA IN THE DISPASE-INJECTED PVR AND SALINE-CONTROL EYES.
Scotopic ERG (-25 dB Flash, Fix On, BackLight Off 0.5 HZ)
    amplitude p-value
a-wave saline-injected control eyes 10.817±4.6006/uV 0.2120(>0.05)
  dispase-injected PVR eyes 8.0143±4.3735/uV  
b-wave saline-injected control eyes 100.00±29.698/uV 0.001(<0.05)
  dispase-injected PVR eyes 19.886±7.774/uV  
Mesopic ERG (0 dB Standard Flash, Fix On, BackLight Off 0.2 HZ)
a-wave saline-injected control eyes 46.167±27.766/uV 0.0110(<0.05)
  dispase-injected PVR eyes 21.836±11.487/uV  
b-wave saline-injected control eyes 180.50±54.099/uV 0.0013(<0.05)
  dispase-injected PVR eyes 48.57±24.747/uV  
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896PHA), there were no immune reactions in dispase- or in saline-
injected mice (Figure 7). Interestingly, there were few IFN-γ
+/CD4+ or IFN-γ+/CD8+ T cells determined by intracellular
staining at a maximum of 4 weeks in dispase-injected mice.
Thus, the IFN-γ found was not secreted by CD4+ or CD8+ T
cells in these mice. It was concluded from these results that
specific immune systems do not play a major role in the
murine dispase-induced PVR model.
When compared with human PVR diseases, the murine
dispase-induced PVR models expressed cardinal features of
PVR  in  this  study.  Our  data  clearly  showed  that  specific
immune systems were not involved in the development of
Figure 7. Enzyme-Linked ImmunoSpot (ELISpot) assay of interferon (INF) -γ in single T cell suspensions from dispase-injected and saline-
injected mouse spleens. A: Compared with positive control group (stimulated with phytohemagglutinin, PHA), IFN-γ values were only detected
at 4-week and 8-week time points in dispase-injected mice, and not detected at any time point in saline-injected mice. B: In the graph of
counting statistics, there were only 25.5 points at the 4-week time point, and 2.5 points in the 8-week for dispase-injected mice.
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897PVR. Despite the prevalence of the autoimmune hypothesis
for  PVR,  the  present  treatment  of  human  PVR  in  clinics
targets  inflammation  and  proliferation.  Triamcinolone
acetonide is being used as an anti-inflammatory drug for early-
stage treatment, and 5-Fluorouracil (5-FU) is being used as an
antiproliferation drug in advanced-stage treatment [44,45].
Therefore, dispase-induced murine PVR indeed models the
human disease and can help us select drugs to treat PVR
successfully.
In  conclusion,  our  data  show  that  neutrophils  in  the
anterior chamber and PVR-like signs in the retinas were found
and that specific immune reactions were not involved after
intravitreal dispase injection in mice.
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